Commercial law firm Hill Dickinson has advised private equity firm NorthEdge on its multi-million-pound investment into Antibody Analytics, a leading provider of immunology research services.
Antibody Analytics is a contract research organisation (CRO) that provides services in the field of pre-clinical drug discovery to an international client base of biopharmaceutical companies.
The strategic investment represents an exciting new chapter for the organisation, which will include significant job creation and expansion of its site, together with investment in high-tech equipment, to create world-class facility with additional capacity and research capabilities.
Founded in 2015, the ability to turbo-charge the growth of Antibody Analytics at this point will reinforce its position as a recognised global leader in pre-clinical immunology research services.
Hill Dickinson’s Private Equity team, led by partners David Mkhitarian and James Down, and senior associate Graeme Anderson, provided advice to NorthEdge, with support from Tasha Millar (corporate), Kathryn Wilson (employment), James Lonsdale (commercial), Patrick Reade (commercial), Jodie Wootton (commercial), Saba Mumraz (commercial), James Lock (commercial), Joyce Tai (commercial), David Baines (commercial), Eleanor Tunnicliffe (commercial), Paula Warnock (pensions), Frances Bailey (pensions) and Steven Betts (tax).
David Mkhitarian said: “We were delighted to have supported NorthEdge on another healthcare investment. Deals like this not only demonstrate the speed and incredible pace of innovation in life sciences but the willingness of investors to support businesses like Antibody Analytics to grow their market share on a world stage.”
James Down added “This is another fantastic deal for our Private Equity team. It was a pleasure to work with the team at NorthEdge and support them on their latest investment. The partnership with Antibody Analytics is a great fit and with NorthEdge’s backing, the business has the perfect platform to continue with its next stage of growth.”
Liam May, Director at NorthEdge, added: “We are committed to investing in people, technology and infrastructure to support businesses that improve global health outcomes.
“Antibody Analytics has a track record of developing strategically important services, alongside a pipeline of R&D projects that will further cement its reputation as a leader in its field. The value creation plan leverages the company’s culture of innovation and blends it with a continued focus on quality, client service and a market-leading employee value proposition to facilitate scale.”
